Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$14.73 USD
-0.70 (-4.54%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.73 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Arcus Biosciences, Inc. (RCUS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.63 | $70.00 | $24.00 | 169.80% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Arcus Biosciences, Inc. comes to $41.63. The forecasts range from a low of $24.00 to a high of $70.00. The average price target represents an increase of 169.8% from the last closing price of $15.43.
Analyst Price Targets (8 )
Broker Rating
Arcus Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy, representing 90% of all recommendations. A month ago, Strong Buy represented 90%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/13/2024 | Mizuho SecuritiesUSA | Salim Syed | Not Available | Strong Buy |
1/30/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
1/16/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
11/8/2023 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 10 |
Average Target Price | $41.63 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.97 |